Goldman Sachs analyst Salveen Richter moved its rating on Taysha Gene Therapies (TSHA) to Buy with an $11 price target from Early-Stage Biotech designation. The firm is positive on the company’s outlook in Rett syndrome. believe Taysha can achieve the response rate of 33% needed to meet the minimum threshold for success in the REVEAL study, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Taysha price target raised to $19 from $13 at Cantor Fitzgerald
- Citizens JMP healthcare analysts hold an analyst/industry conference
- FDA appoints Richard Pazdur as Director of CDER
- Taysha Gene Therapies price target raised to $8 from $6 at Citizens JMP
- Taysha Gene Therapies Advances TSHA-102 Program